Avidity Biosciences' CEO Sarah Boyce discusses the company's Exon 44 skipping data in DMD that showed a 25% increase in dystrophin production
She describes how this PMO based antibody oligonucleotide conjugate works and why she believes the result validates her belief that Avidity has the strongest delivery in the field.